I would rather have some money in a spec with a pharmaceutical product such as Ropren, supposedly about to commence sales in Russia, then a bank or financial failure in the US or Australia for now. I see more upside to SLA rather than liquidation of assets and bad debt.
That may all turn around but for now risk/reward is back in favour of SLA. Particularly with some Opes judgements on the cards.
Does not mean I will not trade the others but the WEST is not the BEST in my books for now!
I would rather have some money in a spec with a pharmaceutical...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $12.14M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 20.5¢ | 20.5¢ | $296 | 1.445K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13294 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 12933 | 1 |
View Market Depth
| Last trade - 14.57pm 12/09/2025 (20 minute delay) ? |
| SLA (ASX) Chart |